Screener
Arbutus Biopharma Corporation ABUS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $4,474 | $5,459 |
| Lease liability, current | 631 | 547 |
| Total current liabilities | 5,105 | 6,006 |
| Liability related to sale of future royalties | 3,278 | 3,442 |
| Contingent consideration | 8,604 | 8,395 |
| Lease liability, non-current | — | 199 |
| Total liabilities | 16,987 | 18,042 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's total current liabilities?
- Arbutus Biopharma Corporation (ABUS) reported total current liabilities of $5.11M in Q1 2026.
- How has Arbutus Biopharma Corporation's total current liabilities changed year-over-year?
- Arbutus Biopharma Corporation's total current liabilities decreased by 73.7% year-over-year, from $19.43M to $5.11M.
- What is the long-term trend for Arbutus Biopharma Corporation's total current liabilities?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's total current liabilities has grown at a -8.8% compound annual growth rate (CAGR), from $9.54M to $6.01M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Arbutus Biopharma Corporation's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude